课题基金 / 基金详情

Mechanisms of Hepatitis C virus induced hepatocyte injury.

Mechanisms of Hepatitis C virus induced hepatocyte injury.
丙型肝炎病毒诱导肝细胞损伤的机制。
批准号:
G0801976/1
负责人:
Jane McKeating
金额:
$44.37万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2009
资助国家:
英国
项目状态:
已结题
起止时间:
2009 至 --

项目摘要

项目成果

Jane McKeating的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
HCV disease is a global problem, with over 2% of the world?s population infected, some 180 million people. Although the disease may take decades to progress, the majority of chronically infected people will eventually show signs of liver damage. In the last few years the incidence of HCV-associated liver failure has increased considerably in the U.K. and several studies have predicted a further 50 - 100% increase in the next decade. HCV-associated liver failure is now the leading indicator for liver transplantation in the UK. Unfortunately the only current therapy (pegylated interferon + ribavirin) is expensive, has significant side effects and is often ineffective. Hence, there is an urgent need for new approaches to treat this disease.One of the prime functions of the liver is the synthesis of bile, which is kept separate from the blood supply by a polarized barrier between the biliary vessels and the rest of the liver. Several manifestations of liver injury associated with HCV infection involve some degree of failure of this biliary system, leading to the liver being damaged by bile acid. HCV entry into cells involves proteins involved in cell polarization, notably the tight junction protein Claudin?1. We have shown that HCV infected cells have an altered polarity and express excessive quantities of Vascular Endothelial Growth Factor (VEGF), a protein which disrupts cell polarization. Depolarisation is mediated via two structural components of the virus, the envelope proteins E1 and E2, that sequester Claudin-1 protein within the cell and stimulate VEGF expression. Treatment of HCV infected cultures with an antibody that inhibits VEGF activity abrogates new rounds of HCV infection, providing an exciting new avenue for antiviral intervention. It is worth noting that, if this approach is validated during the course of this study, suitable VEGF antagonists are already approved for the treatment of various advanced cancers, and we would anticipate the process of drug development to be considerably accelerated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
In-depth structural characterization of the tetraspanin CD81
  • 批准号:
    BB/N008553/2
  • 项目类别:
    Research Grant
  • 资助金额:
    $6.57万
  • 财政年份:
    2017
  • 负责人:
    Jane McKeating
  • 依托单位:
In-depth structural characterization of the tetraspanin CD81
  • 批准号:
    BB/N008553/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $6.57万
  • 财政年份:
    2016
  • 负责人:
    Jane McKeating
  • 依托单位:
The role of Hepatitis C virus glycoprotein-receptor polymorphism in viral pathogenesis
  • 批准号:
    G1100247/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $159.09万
  • 财政年份:
    2012
  • 负责人:
    Jane McKeating
  • 依托单位:
The role of neutralising antibodies in hepatitis C virus infection
  • 批准号:
    G0400802/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $82.82万
  • 财政年份:
    2006
  • 负责人:
    Jane McKeating
  • 依托单位:
国内基金
海外基金
新生期接种乙肝疫苗(hepatitis B vaccine,HBV)影响小鼠情绪相关行为及其机制研究
  • 批准号:
    31600836
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2016
  • 负责人:
    杨俊华
  • 依托单位: